GILD logo Gilead Sciences +
Gilead Sciences
+
Revenue breakdown by Products & Services
Revenue breakdown by Geography

Gilead Sciences's Revenue by Segment

In fiscal year 2025, Gilead Sciences's revenue by segment (products & services) are as follows:

  • Cell Therapy Products, Total Cell Therapy Product Sales: $2.18 B
  • Other Products, Total Other product sales: $799.00 M
  • Products, Other HIV: $20.75 B
  • Trodelvy: $1.40 B
  • Veklury: $911.00 M

Learn more about Gilead Sciences’s Revenue by Geography

Check out competitors to Gilead Sciences in a side-by-side comparison.

Explore additional financial metrics for Gilead Sciences.

Continue reading...

The above chart shows Gilead Sciences's revenue percentage share by segment (products and services).

In fiscal year 2023, Gilead Sciences's revenue by segment is as follows:

  • Cell Therapy Products, Total Cell Therapy Product Sales generated $2.24 B in revenue, representing 2.82% of its total revenue.
  • Corporate Investments generated $7.00 M in revenue, representing 0.01% of its total revenue.
  • Hepatitis B Virus / Hepatitis Delta Virus Product generated $1.02 B in revenue, representing 1.28% of its total revenue.
  • Other Products, Total Other product sales generated $859.00 M in revenue, representing 1.08% of its total revenue.
  • Personal Systems Group generated $35.68 B in revenue, representing 44.99% of its total revenue.
  • Printing generated $18.03 B in revenue, representing 22.73% of its total revenue.
  • Products, Other HIV generated $18.23 B in revenue, representing 22.99% of its total revenue.
  • Trodelvy generated $1.06 B in revenue, representing 1.34% of its total revenue.
  • Veklury generated $2.18 B in revenue, representing 2.75% of its total revenue.

The biggest segment for Gilead Sciences is the Personal Systems Group, which represents 44.99% of its total revenue.
The smallest segment for Gilead Sciences is the Corporate Investments, which represents 0.01% of its total revenue.

The above chart shows Gilead Sciences's revenue percentage share by segment (products and services).

In fiscal year 2024, Gilead Sciences's revenue by segment is as follows:

  • Cell Therapy Products, Total Cell Therapy Product Sales generated $2.38 B in revenue, representing 2.99% of its total revenue.
  • Corporate Investments generated $25.00 M in revenue, representing 0.03% of its total revenue.
  • Other Products, Total Other product sales generated $889.00 M in revenue, representing 1.12% of its total revenue.
  • Personal Systems Group generated $36.20 B in revenue, representing 45.5% of its total revenue.
  • Printing generated $17.34 B in revenue, representing 21.8% of its total revenue.
  • Products, Other HIV generated $19.61 B in revenue, representing 24.65% of its total revenue.
  • Trodelvy generated $1.32 B in revenue, representing 1.65% of its total revenue.
  • Veklury generated $1.80 B in revenue, representing 2.26% of its total revenue.

The biggest segment for Gilead Sciences is the Personal Systems Group, which represents 45.5% of its total revenue.
The smallest segment for Gilead Sciences is the Corporate Investments, which represents 0.03% of its total revenue.

The above chart shows Gilead Sciences's revenue percentage share by segment (products and services).

In fiscal year 2025, Gilead Sciences's revenue by segment is as follows:

  • Cell Therapy Products, Total Cell Therapy Product Sales generated $2.18 B in revenue, representing 8.38% of its total revenue.
  • Other Products, Total Other product sales generated $799.00 M in revenue, representing 3.07% of its total revenue.
  • Products, Other HIV generated $20.75 B in revenue, representing 79.69% of its total revenue.
  • Trodelvy generated $1.40 B in revenue, representing 5.36% of its total revenue.
  • Veklury generated $911.00 M in revenue, representing 3.5% of its total revenue.

The biggest segment for Gilead Sciences is the Products, Other HIV, which represents 79.69% of its total revenue.
The smallest segment for Gilead Sciences is the Other Products, Total Other product sales, which represents 3.07% of its total revenue.
Continue reading...

Summary Table

Products & Services (Percent Share) 2023 2024 2025
Printing 22.73% 21.8% -
Personal Systems Group 44.99% 45.5% -
Corporate Investments 0.01% 0.03% -
Veklury 2.75% 2.26% 3.5%
Cell Therapy Products, Total Cell Therapy Product Sales 2.82% 2.99% 8.38%
Hepatitis B Virus / Hepatitis Delta Virus Product 1.28% - -
Other Products, Total Other product sales 1.08% 1.12% 3.07%
Products, Other HIV 22.99% 24.65% 79.69%
Trodelvy 1.34% 1.65% 5.36%
Total Revenue 100% 100% 100%

The above chart shows the revenue trend of different segments of Gilead Sciences.

In fiscal year 2025, the Products, Other HIV generated the most revenue ($20.75 B), and the Other Products, Total Other product sales generated the least revenue ($799.00 M).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Cell Therapy Products, Total Cell Therapy Product Sales revenue decreased -8.12% ($193.00 M) from $2.38 B (in 2024) to $2.18 B (in 2025).
  • Corporate Investments revenue decreased -100% ($25.00 M) from $25.00 M (in 2024) to $0.00 (in 2025).
  • Other Products, Total Other product sales revenue decreased -10.12% ($90.00 M) from $889.00 M (in 2024) to $799.00 M (in 2025).
  • Personal Systems Group revenue decreased -100% ($36.20 B) from $36.20 B (in 2024) to $0.00 (in 2025).
  • Printing revenue decreased -100% ($17.34 B) from $17.34 B (in 2024) to $0.00 (in 2025).
  • Products, Other HIV revenue increased 5.81% ($1.14 B) from $19.61 B (in 2024) to $20.75 B (in 2025).
  • Trodelvy revenue increased 6.24% ($82.00 M) from $1.32 B (in 2024) to $1.40 B (in 2025).
  • Veklury revenue decreased -49.36% ($888.00 M) from $1.80 B (in 2024) to $911.00 M (in 2025).
    • Continue reading...

    Summary Table

    Products & Services 2023
    Value Change
    		2024
    Value Change
    		2025
    Value Change
    Cell Therapy Products, Total Cell Therapy Product Sales $2.24 B - $2.38 B
    6.12%
    		$2.18 B
    8.12%
    Corporate Investments $7.00 M - $25.00 M
    257.14%
    		- -
    Hepatitis B Virus / Hepatitis Delta Virus Product $1.02 B - - - - -
    Other Products, Total Other product sales $859.00 M - $889.00 M
    3.49%
    		$799.00 M
    10.12%
    Personal Systems Group $35.68 B - $36.20 B
    1.43%
    		- -
    Printing $18.03 B - $17.34 B
    3.83%
    		- -
    Products, Other HIV $18.23 B - $19.61 B
    7.58%
    		$20.75 B
    5.81%
    Trodelvy $1.06 B - $1.32 B
    23.71%
    		$1.40 B
    6.24%
    Veklury $2.18 B - $1.80 B
    17.63%
    		$911.00 M
    49.36%
    Total Revenue $79.31 B - $79.55 B
    0.30%
    		$26.04 B
    67.26%

    Frequently Asked Questions

    What was Gilead Sciences's largest product segment last year?

    In fiscal year 2025, Products, Other HIV revenue reached $20.75 Billion, representing 79.69% of Gilead Sciences's total revenue and making it the largest segment for the company.

    Which product segment experienced the highest growth for Gilead Sciences last year?

    The Trodelvy segment is Gilead Sciences's highest growth segment, with a revenue growth of +6.24% in 2025 compared to 2024.

    Related company

    Revenue Ranking

    Revenue Ranking

    Related

    Submit feedback to Bullfincher